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Streptococcus pneumoniae isolates (6,958) were collected from patients at 163 U.S. medical centers during 2009 through 2012.
Isolates were evaluated for multidrug resistance (MDR) to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim-
sulfamethoxazole, and levofloxacin. Ceftaroline was 16-fold more potent than ceftriaxone (MIC50/MIC90,<0.25/2g/ml)
against all isolates. For MDR isolates (35.2% of tested strains), ceftaroline (MIC50/MIC90, 0.06/0.25g/ml; 100.0% susceptible)
was the most active agent tested, being 8-fold more potent than ceftriaxone (MIC50/MIC90, 0.5/2g/ml) and 16-fold more potent
than penicillin (MIC50/MIC90, 1/4g/ml).
Ceftaroline fosamil is a parenteral prodrug which is rapidlyhydrolyzed in vivo to release the active agent ceftaroline (1, 2).
Ceftaroline displays broad-spectrum in vitro activity against
Staphylococcus aureus, including methicillin-resistant strains
(MRSA), Streptococcus pneumoniae, including multidrug-resis-
tant (MDR) strains, and Enterobacteriaceae which do not produce
extended-spectrum -lactamases (ESBL) (3–13). Ceftaroline acts
in the same manner as other -lactams by inhibiting essential
penicillin-binding proteins (PBPs); however, its affinity for al-
tered PBPs (PBP2A in MRSA and PBP1A, -2B, and -2X in S. pneu-
moniae) allows it to be active against strains with elevated MICs to
other -lactams (14, 15).
The Assessing Worldwide Antimicrobial Resistance Evalua-
tion (AWARE) program monitors the activities of ceftaroline and
comparator agents tested against pathogens causing either respi-
ratory or skin and soft tissue infections (3, 6, 7, 16). The program
is in its fifth year for the United States, providing longitudinal
information on the antimicrobial activities of ceftaroline and
comparator agents. In this report, we present an analysis of the
activity of ceftaroline and comparators tested by reference meth-
ods against S. pneumoniae isolates collected during the 2009-2012
surveillance program, with an emphasis on the activity against
resistant subsets (e.g., resistant to two or more antimicrobial
classes).
(This work was presented in part in abstract form at IDWeek in
San Francisco, CA [October 2013].)
A total of 6,958 isolates were collected from patients in 163 U.S.
medical centers. Respiratory tract pathogens were collected from
patients with community-acquired and nosocomial respiratory
tract infections (RTI). Isolates were submitted to the central mon-
itoring laboratory (JMI Laboratories, North Liberty, IA, USA) for
confirmatory identification and susceptibility testing. The major-
ity of these isolates were from lower respiratory tract infections,
with approximately 20% being from the upper respiratory tract
(data not shown). Only isolates deemed clinically relevant by the
submitting laboratory were included.
Broth microdilution tests were conducted at the central refer-
ence laboratory according to Clinical and Laboratory Standards
Institute (CLSI) methods to determine susceptibility to ceftaro-
line and comparator antimicrobials (17). Validated MIC panels
were manufactured by ThermoFisher Scientific (Cleveland, OH,
USA). S. pneumoniae isolates were tested in cation-adjusted Mu-
eller-Hinton broth supplemented with 2.5 to 5% lysed horse
blood according to CLSI document M7-A09 (17). The quality
control strain S. pneumoniae ATCC 49619 was tested concurrently
with clinical isolates. Susceptibility determinations and quality
control validation of results were based on CLSI guidelines (17,
18). The ceftaroline susceptibility breakpoint applied in this
study was0.5 g/ml (CLSI and USA-FDA susceptibility break-
point) (17–19).
Multidrug resistance (MDR) status was determined based on
nonsusceptibility (NS) to the antimicrobial agents penicillin,
ceftriaxone, levofloxacin, tetracycline, trimethoprim-sulfame-
thoxazole, and erythromycin. MDR isolates were defined as those
that were NS to at least two of the above antimicrobial agents
(MDR 2). Further analyses were done for S. pneumoniae isolates
that tested as NS to at least three of the above (NS 3), four of the
above (NS 4), and five of the above agents (NS 5).
The most frequently occurring NS phenotypic patterns are
presented in Table 1. The most common pair of antimicrobials
for which the NS phenotype was seen was erythromycin plus
trimethoprim-sulfamethoxazole (1,866 occurrences) (Table
1). The most common combination of three antimicrobials for
which the NS phenotype was seen was erythromycin plus tetra-
cycline plus trimethoprim-sulfamethoxazole (1,401 occur-
rences), and that for four antimicrobials was penicillin plus
erythromycin plus tetracycline plus trimethoprim-sulfame-
thoxazole (856 occurrences). The most common NS phenotype
pattern for five antimicrobials was penicillin plus ceftriaxone
plus erythromycin plus tetracycline plus trimethoprim-sulfa-
methoxazole (645 occurrences), and there were 13 occurrences
of NS to all six antimicrobials evaluated.
Among the 6,958 S. pneumoniae isolates, 12.0% (831) were
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penicillin intermediate (Pen-I; MIC, 4 g/ml) and 1.5% (106)
were penicillin resistant (Pen-R; MIC, 8 g/ml) (Table 2). A
total of 10.8% (750) of all isolates were NS to ceftriaxone, with a
MIC of 2 g/ml (Table 2). For cefuroxime and amoxicillin/
clavulanate, NS rates were 28.2 and 16.7%, respectively (Table 3).
There was a high rate of resistance to erythromycin at 42.7%, and
resistance to tetracycline, trimethoprim-sulfamethoxazole, and
clindamycin ranged from 20.3 to 24.6% (Table 3). For the antimi-
crobials listed in Table 3, high rates of susceptibility were seen only
for ceftaroline and levofloxacin (100.0 and 98.9%, respectively)
(Table 3). Ceftaroline (MIC50/MIC90, 0.015/0.12 g/ml) was
16-fold more potent than ceftriaxone (MIC50/MIC90,0.25/2g/
ml) and 64-fold more potent than cefuroxime (MIC50/MIC90,
2/8 g/ml) (Table 3). A total of 66.0 and 100.0% of Pen-R iso-
lates (MIC,8g/ml) were inhibited by ceftaroline at0.25 and
0.5 g/ml, respectively (Table 2). Ceftaroline activity remained
consistent through the study period, with a MIC50/MIC90 for all S.
pneumoniae isolates of 0.015/0.12 g/ml, which varied only in
2009 (0.015/0.25g/ml) (data not shown). The percentage of S.
pneumoniae isolates with the highest ceftaroline MICs, 0.5g/ml,
ranged from 0.5 (2012) to 1.5% (2009). Limited variation in over-
all susceptibility occurred for other antimicrobials. Amoxicillin-
clavulanate susceptibility by year ranged from 81.0 to 85.7%,
erythromycin susceptibility ranged from 55.3 to 61.2%, clindamy-
cin susceptibility ranged from 77.5 to 81.2%, and tetracycline sus-
ceptibility ranged from 73.8 to 75.7% (data not shown).
For MDR S. pneumoniae isolates (2,449 isolates), susceptibility
to ceftaroline was 100.0%, whereas susceptibilities to penicillin
(61.8%; MIC,2 g/ml [susceptibility breakpoint for parenteral
nonmeningitis strains]), ceftriaxone (69.6%), and amoxicillin-
clavulanate (58.0%) were markedly reduced (Table 3). Ceftaroline
was the most active agent tested against MDR isolates, with a
MIC50 and MIC90 of 0.06 and 0.25 g/ml, respectively (Table 2).
This was 8-fold more active than ceftriaxone (ceftriaxone MIC50/
MIC90, 0.5/2 g/ml) and 16-fold more potent than penicillin
(penicillin MIC50/MIC90, 1/4 g/ml) (Table 3). Only 16.5 and
61.8% of MDR isolates were inhibited at0.06 and2 g/ml of
penicillin, respectively, while 97.3 and 100.0% were inhibited at
0.25 and0.5 g/ml of ceftaroline, respectively (Table 2).
The subset of S. pneumoniae isolates that were NS to3 drugs
(1,509 strains) also exhibited 100.0% susceptibility to ceftaroline
(Table 3). Susceptibility was further decreased for all other agents
among the S. pneumoniae isolates that were NS to3 drugs com-
pared to the larger MDR group. For example, the proportion of
strains susceptible to penicillin was 38.6% (MIC,2 g/ml [sus-
ceptibility breakpoint for parenteral nonmeningitis strains]), the
proportion susceptible to ceftriaxone was 51.4%, and the propor-
tion susceptible to amoxicillin-clavulanate was 35.3% (Table 3).
Ceftaroline was the most active agent against S. pneumoniae iso-
lates that were NS to3 drugs, exhibiting a MIC50 and MIC90 of
0.12 and 0.25 g/ml, respectively (Table 3), which were 8- and
16-fold more active than ceftriaxone (MIC50/MIC90, 1/2 g/ml)
and penicillin (MIC50/MIC90, 4/4 g/ml), respectively (Table 3).
For S. pneumoniae isolates which were NS to 4 drugs (948
isolates) or 5 drugs (646 isolates), rates of susceptibility to cef-
taroline remained at 100.0% (Table 3). Rates of susceptibility to
the other antimicrobial agents, however were decreased as was
noted previously for S. pneumoniae isolates when grouped as
MDR or NS3 (Table 3). Susceptibility in the NS5 group was
10% for all agents except for ceftaroline (100.0%) and levofloxa-
cin (97.8%) (Table 3).
In summary, ceftaroline demonstrated potent in vitro activity
against a collection of contemporary S. pneumoniae isolates from
U.S. medical centers, including isolates resistant to many com-
monly available antimicrobials, such as ceftriaxone. All S. pneu-
moniae isolates tested were susceptible to ceftaroline, but contin-
TABLE 1 Most frequently occurring non-drug-susceptible (NS) phenotype patterns
No. of
drugsa
Most common pattern (no. of occurrences)b
First Second Third
Two ERY TMP/SMX (1,866) ERY TET (1,847) TET TMP/SMX (1,509)
Three ERY TET TMP/SMX (1,401) PEN ERY TMP/SMX (909) PEN ERY TET (865)
Four PEN ERY TET TMP/SMX (856) PEN CRO ERY TMP/SMX (684) CRO ERY TET TMP/SMX (671)
Five PEN CRO ERY TET TMP/SMX (645) CRO ERY TETTMP/SMX LEV (14) PEN CRO ERY TET LEV (13)
Six PEN CRO ERY TET TMP/SMX LEV (13)
a Number of drugs to which isolates were nonsusceptible.
b Penicillin (PEN), ceftriaxone (CRO), levofloxacin (LEV), tetracycline (TET), trimethoprim-sulfamethoxazole (TMP/SMX), and erythromycin (ERY) were used to categorize
multidrug resistance (six antimicrobial classes). Patterns are listed as most common (first), second most common, and third most common.
TABLE 2 Cumulative frequency of MIC distribution for ceftaroline tested against 6,958 S. pneumoniae isolates (United States, 2009 to 2012)
S. pneumoniae isolates (no.)a
No. (cumulative %) with a ceftaroline MIC (g/ml) of: MIC (g/ml)
0.015 0.03 0.06 0.12 0.25 0.5 50% 90%
Total (6,958) 4,224 (60.7) 591 (69.2) 612 (78.0) 992 (92.3) 473 (99.1) 66 (100.0) 0.015 0.12
Isolates with penicillin MIC of8 g/ml (106) 1 (0.9) 3 (3.8) 66 (66.0) 36 (100.0) 0.25 0.5
Isolates with penicillin MIC of 4 g/ml (831) 6 (0.7) 407 (49.7) 390 (96.6) 28 (100.0) 0.25 0.25
Isolates with ceftriaxone MIC of2 g/ml (750) 2(0.3) 4 (0.8) 264 (36.0) 415 (91.3) 65 (100.0) 0.25 0.25
MDR isolates NS to2 drugs (2,449) 548 (22.4) 274 (33.6) 431 (51.2) 661 (78.2) 469 (97.3) 66 (100.0) 0.06 0.25
Isolates NS to3 drugs (1,509) 132 (8.7) 130 (17.4) 201 (30.7) 513 (64.7) 468 (95.7) 65 (100.0) 0.12 0.25
Isolates NS to4 drugs (948) 6 (0.6) 3 (0.9) 17 (2.7) 397 (44.6) 461 (93.2) 64 (100.0) 0.25 0.25
Isolates NS to5 drugs (646) 1 (0.2) 209 (32.5) 385 (92.1) 51 (100.0) 0.25 0.25
a MDR, multidrug resistant; NS, nonsusceptible (includes isolates that test as intermediate or resistant).
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ued surveillance is warranted to track the activity of ceftaroline
and other important antimicrobial agents.
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